Aura Biosciences AURA 深 滬
已收盤 07-10 16:00:00 美东时间
6.84
-0.160
-2.29%
華盛通- 最 高7.30
- 今 開7.00
- 成交量 44.28万股
- 最 低 6.64
- 昨 收 7.00
- 總市值 7.08亿
- 52周最高 9.535
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 4.73
- 委 比 -96.30%
- 總股本 1.03亿
- 歷史最高 26.16
- 量 比 0.51
- 振 幅 9.43%
- 歷史最低 4.345
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aura Biosciences strengthens board with new independent director
Aura Biosciences Inc ( ($AURA) ) just unveiled an update. On July 3, 2026, Aura...
07-08 19:48
Aura Biosciences appoints Jeremy Bender to board of directors
Aura Biosciences appoints Jeremy Bender to board of directors Aura Biosciences appointed Jeremy Bender to its board of directors. Bender previously served as CEO and president of Day One Biopharmaceuticals, leading the approval and launch of OJEMDA. He also led Day One through its roughly $2.5 billi
07-08 19:04
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences appoints Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender, a biotech leader with experience in advancing therapies and commercialization, joins as the company prepares for potential regulatory approval of bel-sar for early choroidal melanoma. Aura aims to develop precision therapies preserving organ function, with bel-sar in late-stage development. Bender previously led Day One Biopharmaceuticals through its $2.5 b...
07-08 11:01
Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027
Topline data for the 15-month primary endpoint are anticipated in the second half of 2027."Completing enrollment in our Phase 3 CoMpass trial marks a significant milestone for Aura as we advance bel-sar toward a
06-01 20:14
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic May 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aecom, Humana and Mosaic on Wednesday. HIGHLIGHTS * Aecom ACM.N : RBC cuts target price to $111 from $142 * Humana HUM.N
05-13 15:31
Aura Biosciences Q1 EPS $(0.50) Misses $(0.39) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.39) by 28.21 percent. This is a 9.09 percent increase over losses of $(0.55) per share from
05-12 05:30
Aura Biosciences reports Q1 results, appoints new CEO
Aura Biosciences Inc ( ($AURA) ) has shared an update. On May 11, 2026, Aura Bi...
05-12 05:04
美股牛股 | 多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%
多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%，获Long Lake以63亿美元收购>>
05-05 18:24
Aura Biosciences Announces Stock Repurchase Agreement with Shareholder
Aura Biosciences Inc ( ($AURA) ) just unveiled an update. On April 30, 2026, Au...
05-05 05:39
Aura Biosciences Prices ~$260.3M Offering Of Common Shares, Pre-Funded Warrants
Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten
05-04 21:09
